Identification of promiscuous small molecule activators in high-throughput enzyme activation screens.
暂无分享,去创建一个
Paul J Hergenrother | P. Hergenrother | J. Heeres | David R. Goode | R. K. Totten | James T Heeres | Ryan K Totten | David R Goode
[1] B. Shoichet,et al. High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.
[2] D. Pereira,et al. Origin and evolution of high throughput screening , 2007, British journal of pharmacology.
[3] R. Silverman,et al. Small-molecule activators of RNase L with broad-spectrum antiviral activity , 2007, Proceedings of the National Academy of Sciences.
[4] The dual role of CHAPS in the crystallization of stromelysin-3 catalytic domain. , 2003, Acta crystallographica. Section D, Biological crystallography.
[5] J. Broach,et al. High-throughput screening for drug discovery. , 1996, Nature.
[6] O. V. Evgenov,et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.
[7] B. Shoichet. Screening in a spirit haunted world. , 2006, Drug discovery today.
[8] P. Hergenrother,et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy , 2006, Nature chemical biology.
[9] E. G. Delmar,et al. A sensitive new substrate for chymotrypsin. , 1979, Analytical biochemistry.
[10] Brian K Shoichet,et al. A detergent-based assay for the detection of promiscuous inhibitors , 2006, Nature Protocols.
[11] Christopher P Austin,et al. A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.
[12] J. Lakowicz,et al. On the effect of sodium dodecyl sulfate on the structure of beta-galactosidase from Escherichia coli. A fluorescence study. , 2001, Journal of biochemistry.
[13] J. Mankovich,et al. Substrate Specificities of Caspase Family Proteases* , 1997, The Journal of Biological Chemistry.
[14] B. Shoichet,et al. Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.
[15] Paul J Hergenrother,et al. Obtaining and screening compound collections: a user's guide and a call to chemists. , 2006, Current opinion in chemical biology.
[16] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[17] B. Posner,et al. High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics. , 2005, Current opinion in drug discovery & development.
[18] Amy V. Lynch,et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.
[19] J. Grimsby,et al. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. , 2006, Current medicinal chemistry.
[20] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[21] J. Grippo,et al. Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.